Ninety male patients with acute nongonococcal urethritis (NGU) who presented for follow-up 10-92 days after initiation of treatment were evaluated. A polymerase chain reaction assay and direct fluorescence antibody test were used to detect Chlamydia trachomatis at presentation and during follow-up. Chlamydial heat-shock protein 60 kD (hsp60) serology with an enzyme-linked immunosorbent assay and C. trachomatis serology with a microimmunofluoresence test were undertaken. In 62 (69%) of the men, evidence of chronic urethritis was noted during follow-up. C. trachomatis was detected in only two patients during follow-up. Chlamydial hsp60 antibody was associated with the development of chronic urethritis between 10 and 92 days after treatment began (P < .04), that is, at 10-29 days (P < .02) and at 30-92 days (P < .008). These results are consistent with the theory that immune response to hsp60 is important in the development of this chronic disease. The results also suggest that chronic NGU is not a consequence of continued production of hsp60 by C. trachomatis.
Acute nongonococcal urethritis (NGU), characterized by urethral discharge and/or dysuria and/or penile tip irritation, is the response of the urethra to inflammation. In 1993-1994 -60,000 cases of NGU were diagnosed in the United Kingdom [1] , and it has been estimated that 2 million cases occur per year in the United States [2] . Chlamydia trachomatis causes ocular-genital tract inflammation and in men accounts for -30%-50% of cases of acute NGU. Ureaplasma urealyticum [3] and Mycoplasma genitalium [4, 5] have also been associated with NGU, but in a substantial proportion of cases the cause remains unknown, although it is extremely unusual for the disease to occur in men who are not sexually active.
Despite appropriate antibiotic therapy, 30%-60% of patients will have persistent or recurrent (chronic) urethritis after 1-2 weeks of treatment; the cause is unclear [6] [7] [8] , since the development of chronic disease is independent of the detection of C. trachomatis at presentation [9] . Nevertheless, a feature of infection by Chlamydia species is the development of chronic inflammatory sequelae. Although it is not entirely clear why this happens, it is believed to be primarily immunologically mediated and not to be a direct consequence of tissue destruction by the organisms [10, 11] .
The results of numerous experimental and epidemiological studies indicate that reinfection with C. trachomatis leads to greater inflammation than does primary infection. This is seen in trachoma [12, 13] , which is considered a disease of ocular hypersensitivity, and repeated infection is also thought to be involved in establishing the chronic inflammation that leads to fallopian tube obstruction and scarring associated with subsequent infertility [14, 15] . Paradoxically, while the immune response may confer partial immunity to subsequent infection, it also results in the pathology and tissue destruction associated with chlamydial disease.
Heat-shock proteins, existing as discrete families, are among the most conserved proteins in phylogeny with respect to both function and structure [16] . These proteins are produced by prokaryotic and eukaryotic cells in response to a variety of insults and can modify the function and destiny of other proteins; thus, they play an important part in numerous physiological processes. The 60-kD chlamydial heat-shock protein (hsp60) has been isolated from the outer membrane of elementary bodies. It has been sequenced and proposed as having a role in the assembly of the chlamydial cell wall [17, 18] .
Morrison et al. [19] were the first to show, in the guinea pig chlamydial ocular model, that chlamydial hsp60, with a sequence homologous to the 60-kD heat-shock protein of Escherichia coli (GroEL), induced a delayed-type hypersensitivity response in immune guinea pigs. This was characterized by a submucosal cellular infiltrate of lymphocytes and monocytes. The immunologic response was similar histologically and clinically to that described in individuals with chronic trachoma.
Subsequently, Wagar et al. [20] and Toye et al. [21] demonstrated that a serological response to the chlamydial hsp60 was associated with chronic sequelae of pelvic inflammatory disease in patients with antibodies to C. trachomatis. This sug-gests that the immune response to chlamydial hsp60 may be important in the pathogenesis of persistent genital tract inflammation in humans. As a consequence, our aim was to determine in a prospective study whether a serological response to the chlamydial hsp60 was associated with persistence or recurrence of NGU after treatment.
Materials and Methods

Patients and Samples
One hundred and thirteen patients with acute NGU were studied. Ninety patients (80%) attended at least once for followup (10-92 days after initiation of treatment) and were evaluable. Of these, 84 were evaluable at 10-29 days and 51 were evaluable at 30-92 days after treatment began. The median age of the ninety evaluable men was 31 years (range, 19-53 years). Forty one (46%) had had an episode of NGU in the past. There were 213 follow-up visits, and the median number of follow-up visits per patient was 2 (range, 1-5).
NGU was diagnosed at initial presentation if there were polymorphonuclear (PMN) leukocytes per high-power (X 1,000) microscope field in five or more fields in a gramstained urethral smear. Patients were considered to be clinically symptomatic if they complained of discharge, dysuria, penile irritation, or genital discomfort or had a urethral discharge on examination after urethral massage. Patients from whom Neisseria gonorrhoeae was cultured were excluded, as were patients with a proven urinary tract infection or genital herpes.
A urethral swab specimen was smeared on a MicroTrak slide (Syva, Milton Keynes, UK), a first-passed-urine (FPU) specimen was obtained, and blood was taken for serology. Patients were treated with doxycycline (200 mg initially and 100 mg/d for 13 days) or erythromycin (500 mg q.i.d. for 14 days) if they were intolerant of doxycycline. They were advised to abstain from sexual intercourse and that their partner(s) needed to receive treatment from a department of genitourinary medicine.
Patients were asked to return for clinical examination and venipuncture after 2 weeks, 6 weeks, and 12 weeks, or more frequently if clinically indicated, and to avoid urinating for 4 hours before each visit. At such follow-up, a urethral gramstained smear was prepared and an FPU specimen was collected if the patient had had NGU at the previous attendance; otherwise, only an FPU specimen was collected. Investigations for patients who had a recurrence of urethritis were the same as those undertaken at the initial visit.
Urethral inflammation was diagnosed at follow-up if there were either (1) PMN leukocytes per high-power field in five or more fields in a gram-stained urethral smear or (2) . -10 PMN leukocytes per high-power field in five or more fields in a gram-stained thread in the FPU specimen. The urethral smear was evaluated first, and only if this was negative or not available was the FPU examined for pyuria.
Patients with persisting urethritis were treated with erythromycin (500 mg q.i.d. for 2 weeks) and metronidazole (400 mg b.i.d. for 5 days) and were again informed that they should abstain from sexual intercourse. If urethritis had resolved, the patients were advised that they could be sexually active again unless their partner(s) had not received treatment, in which case they were again informed that their partner(s) should be treated prior to resuming sexual intercourse. Those patients who had persistent urethritis after 4 weeks' treatment were asked to return 1 week later, when an FPU specimen was collected.
Chronic NGU was defined as the persistence or recurrence of urethral inflammation. When urethritis was present at the patient's first follow-up visit between 10 and 92 days or between 10 and 29 days, it was considered persistent. Urethritis occurring in patients who did not have persistent urethritis at their first follow-up visit was considered recurrent. Persistence between 30 and 92 days was defined by the presence of urethral inflammation in patients whose urethritis persisted up to their first follow-up visit after 29 days.
Detection of C. trachomatis
The MicroTrak direct fluorescent antibody (DFA) test was used to detect C. trachomatis elementary bodies in a urethral smear and in a deposit from an FPU specimen collected at initial presentation. At follow-up visits, only the urine deposit was tested in this way, on at least one occasion. The PCR assay for C. trachomatis was undertaken on specimens from patients at initial presentation. This assay was developed by ourselves and was used as described previously [22] .
The PCR assay was repeated at first follow-up on specimens from those patients who were C. trachomatis-positive at presentation. For any patients with persistent urethritis after 4 weeks' treatment, it was again undertaken at the third followup visit, when they would have completed antibiotic treatment 1 week previously. The PCR assay was performed again for any patient who was cured but subsequently relapsed.
At presentation, a patient was considered C. trachomatispositive if either the DFA test on an urethral smear or FPU specimen was positive or the PCR assay was positive. A patient was considered C. trachomatis-negative at presentation only if any two tests were evaluable; otherwise, the patient was considered unevaluable for C. trachomatis. These tests were undertaken by investigators who were blinded from clinical information or chlamydial hsp60 serological status.
C. trachomatis and Chlamydial hsp60 Serology
Patients were asked to give blood for serological assessment at their first visit, at 2-6 weeks, and again at 12 weeks. The serum was separated and stored at -20°C. Chlamydial serology was undertaken with a microimmunofluorescence test as described previously [23] . Fluorescence at a serum dilution of 1:8 or greater at any time during the study period was considered to be positive. This was undertaken without knowledge of the hsp60 serology results. Hsp60 antibody was detected by an ELISA, which was performed as described previously, with eukaryotic expression vector [24] . Sera were tested at a 1:100 dilution. Samples providing a result within one standard deviation of the optical density (OD) cutoff value were tested again in duplicate, as were random samples yielding results above and below this value. A sample was considered positive if the adjusted OD value was greater than the cutoff value. The cutoff was defined as the mean OD + 3 standard deviations of the negative control sera.
Statistical Analysis
Groups were compared by means of X2 analysis with Yates's correction or Fisher's exact test as well as maximum likelihood estimates of the odds ratio with 95% confidence intervals. This was undertaken with use of Epi-Info software (version 6.01), from the Centers for Disease Control and Prevention (CDC, Atlanta).
Results
Relation of Detection of C. trachomatis and Chlamydial Antibody at Initial Presentation with Development of Chronic Urethritis
Details of the development of chronic NGU are shown in table 1. Of the 90 men seen during follow-up between days 10 and 92, 41 (45%) had a positive urethral smear, 21 (23%) had pyuria, and 28 (31%) had no urethral inflammation. Eightysix patients were evaluable for presence of C. trachomatis, of whom 34 (40%) were positive at their first visit. The presence of C. trachomatis at this initial presentation was not associated with chronic NGU, either between days 10 and 92 or between days 30 and 92'. However, C. trachomatis was associated with the development of chronic NGU between days 10 and 29 (table 2) .
Thus, between days 10 and 29 of follow-up, of 33 men who were C. trachomatis-positive at presentation, 25 (76%) developed chronic urethritis; of 49 who were C. trachomatisnegative, 24 (49%) developed chronic disease (P < .03; OR, 3.2; CI, 1.1-9.9). C. trachomatis was detected in only two patients during follow-up. Similarly, antibody to C. trachomatis was not associated with the development of chronic NGU between days 10 and 92, but it was associated with chronic NGU between days 10 and 29 (table 2) . Thus, of 35 men who were C. trachomatis antibody-positive, 26 (74%) developed chronic urethritis, while of 44 who were C. trachomatis antibodynegative, 22 (50%) developed chronic disease (P < .05; OR, 2.9; CI, 1.0-8.6).
Relation of Sexual Intercourse and History of NGU with Development of Chronic Urethritis
There was no difference in abstinence from sexual intercourse reported either at the first follow-up visit or during the study period for those who had chronic NGU and for those who had no urethritis. Thus, at the first follow-up visit, 38 (45%) had been sexually active, of whom 22 (58%) developed chronic NGU between days 10 and 29, while of 46 patients who had not been sexually active, 29 (63%) developed chronic NGU during this period (P = .80). During the study period, 55 (61%) were sexually active, of whom 38 (69%) developed chronic NGU between days 10 and 92, while of 35 patients who had not been sexually active, 24 (69%) developed chronic NGU (P = .86).
A history of NGU was not associated with chronic NGU. Twenty-six (42%) of 62 men with chronic NGU between days 10 and 92 had a history of NGU, whereas 15 (54%) of 28 men without chronic NGU had a history of NGU (P = .42).
Relation of Detection of C. trachomatis and Chlamydial Antibody at Initial Presentation with Chlamydial hsp60 Serology
The hsp60 antibody status of 85 patients at their initial presentation and of 88 patients during the study period was ana- lysed. Hsp60 serological data were available for 43 patients 30-92 days after commencement of treatment. Thirty-two (38%) were found to have hsp60 antibody at presentation and 36 (41%) during the study. Six patients who were hsp60 antibody-positive at presentation became antibody-negative during follow-up. Four patients who were hsp60 antibody-negative at presentation became positive during follow-up, of whom one subsequently became negative between days 30 and 92. C. trachomatis detection at presentation was significantly associated with the presence of hsp60 antibody. Thus, of 34 patients who were C. trachomatis-positive, 20 (59%) had hsp60 antibody, whereas of 47 patients who were C. trachomatisnegative, only 11 (23%) had hsp60 antibody (P < .003; OR, 4.5; CI, 1.62-13.7). In addition, the presence of C. trachomatis antibody was significantly associated with hsp60 antibody during the study period. Thus, of 38 patients who had C. trachomatis antibody, 25 (66%) had hsp60 antibody, whereas of 46 patients who did not have C. trachomatis antibody, only 9 (20%) had hsp60 antibody (P < .00005; OR, 7.7; CI, 2.7-24).
Relation of hsp60 Antibody to Development of Chronic Urethritis
Hsp60 antibody at presentation was not associated with the development of chronic urethritis at 10-92 days in those patients who were C. trachomatis-positive (table 3) . Thus, of 34 patients who were evaluable and C. trachomatis-positive at 10-92 days, 20 had hsp60 antibody at presentation, and of these, 17 (85%) developed chronic urethritis. Of the 14 patients who did not have hsp60 antibody, 8 (57%) developed chronic disease (P = .12; OR, 4.1; CI, 0.66-32).
However, hsp60 antibody was associated with chronic urethritis at 10-92 days after treatment in those patients who were either C. trachomatis-positive or chlamydial antibody positive (table 3) . That is, of 45 patients who were evaluable between 10 and 92 days, 26 had hsp60 antibody at presentation, and of these, 22 (85%) developed chronic urethritis. Of the 19 patients who did not have hsp60 antibody, 10 (53%) developed chronic disease (P < .05; OR, 4.8; CI, 1.0-27).
When all study patients were considered, irrespective of whether they were C. trachomatis-positive, hsp60 antibody at presentation was also associated with the development of chronic urethritis at 10-92 days (table 3) . Of 32 men who had hsp60 antibody at presentation, 27 (84%) had developed chronic urethritis at 10-92 days after treatment began, whereas of 53 men who did not have hsp60 antibody, 32 (60%) developed chronic disease (P < .04; OR, 3.5; CI, 1.1-13.5).
To investigate further the temporal association of hsp60 antibodies with chronic NGU, we studied the association of hsp60 antibodies, both at presentation and at follow-up, with chronic NGU at 10-29 days and at 30-92 days (tables 4 and 5). At days 10-29 of follow-up, antibodies to hsp60 both at presentation and during follow-up were associated with chronic NGU. Thus, of 30 men who had hsp60 antibody at presentation, 24 (80%) developed chronic NGU, whereas of 49 men who did not have hsp60 antibody, 25 (51%) developed chronic disease (P < .02; OR, 3.8; CI, 1.2-13.3). Of 29 men who were hsp60 antibody-positive during follow-up, 23 (79%) developed Table 3 . Detection of chlamydial heat-shock protein 60 kD (hsp60) antibody at presentation in relation to the persistence or recurrence of urethritis 10-92 days after the commencement of treatment in men with nongonococcal urethritis and chlamydial urethritis. chronic NGU, whereas of 53 men who did not have hsp60 antibody, 27 (51%) developed chronic disease (P < .03; OR, 3.6; CI, 1.2-12.7). However, at days 30-92 of follow-up, antibodies to hsp60 were associated with chronic NGU during follow-up but not at presentation. Thus, of 17 patients with hsp60 antibody at presentation, 12 (71%) developed chronic urethritis, whereas of 31 who did not have hsp60 antibody at presentation, 15 (48%) developed chronic disease (P = .24; OR, 2.5; CI, 0.63-11.4). Of 13 men who had hsp60 antibody during followup and were assessable, 12 (92%) developed chronic urethritis, whereas of 34 who did not have hsp60 antibody during followup, 15 (44%) developed chronic disease (P < .008; OR, 14.4; CI, 1.77-683).
During the study period the number of patients with recurrent NGU was relatively small. It was therefore not possible to perform a separate analysis on that group. Excluding those patients with recurrent urethritis did not alter the findings.
To assess the influence of a history of NGU on the association of hsp60 antibody with chronic NGU, an analysis of the presence of hsp60 antibody, both at presentation and during follow-up, in relation to chronic NGU at 10-92 days, 10-29 days, and 30-92 days, was undertaken for patients with no history of NGU and those with a history of NGU. Only hsp60 antibody noted during follow-up in patients with a history of NGU remained significantly associated with chronic NGU at 30-92 days.
Thus, of 23 patients with a history of NGU, 8 were hsp60 antibody-positive, and 7 (88%) of these developed chronic NGU, whereas only 5 (33%) of 15 hsp60 antibody-negative men developed chronic NGU (P < .03; OR, 12.3; CI, 1.1-692). Of 24 patients with no history of NGU, 5 were hsp60 antibody-positive and all of these developed chronic NGU, whereas only 10 (53%) of 19 hsp60 antibody-negative men developed chronic NGU (P = .12).
Discussion
Chronic NGU is a complex condition, the etiology of which is probably multifactorial [9] . It does not appear to cause any long-term chronic inflammatory damage in men, and its etiology(ies) may therefore differ from those of the chronic sequelae of pelvic inflammatory disease. There is no precise definition of chronic NGU; some investigators rely solely on examination of the urethral smear, while others have analyzed the FPU. We have used both, as we believe that the presence of PMN leukocytes in the anterior urethra defines urethritis. The use of either a urethral smear or an FPU is a valid method of sampling, and we chose not to make a urethral smear for all patients at follow-up for fear of reducing the number of those returning during the study period. The proportion of patients with chronic NGU in our study is larger than in most previously reported studies. Lomas et al. recently demonstrated, using an in vitro assay, that the PMN leukocyte stimulatory response persists many weeks after treatment of acute NGU [25] . This occurs in both C. trachomatispositive and -negative NGU, the stimulatory response in the former being less marked. Our findings are consistent with this observation.
We speculate that the discrepancy between our findings and those of other studies is probably a reflection of the sensitivities of the tests used for assessing urethral inflammation. We assessed both a urethral smear and an FPU specimen for all patients who returned for a test of cure of NGU. Investigations in most other studies used only one of these methods.
A plastic loop is less traumatic and absorbent than a cottontipped swab, and we believe this facilitates a urethral smear of better quality. Directly sampling and gram-staining a urethral thread has not been compared with microscopically examining the centrifuged urine deposit. The method we chose allowed convenient sampling of an FPU specimen and was not dependent on the thread being sedimented during centrifugation, which in our experience does not always happen. However, it would fail to detect pyuria in the FPU specimen, unless the PMN leukocytes are present in visible threads. This hypothesis is supported by the findings of Romanowski et al. [26] ; they demonstrated using urethral smears that 2 weeks after initiating treatment with a tetracycline, 23% of patients still had urethritis. They also noted that many men, although "cured" at follow-up, still had a minimal amount of clear urethral discharge. They believed that this was probably not an indication of significant inflammation. Thus, using different criteria and methodology, they would probably have found more urethritis during follow-up.
In addition, there is no agreed-upon definition of how long urethritis must persist after treatment of acute NGU before it is termed chronic. Investigators in many studies have assessed the response to treatment only at the first follow-up visit. We decided, therefore, to undertake analysis of chronic NGU not only during days 10-92 but also at days 10-29 and days 30-92.
We found no association between the detection of C. trachomatis or antibody to this microorganism in patients who presented with acute NGU and the development of chronic NGU between 10 and 92 days after treatment. We did find that the detection of C. trachomatis or antibody to it was associated with chronic NGU between 10 and 29 days, but not with NGU between 30 and 92 days. Some previous investigators have concluded that C. trachomatis-positive men respond better to antibiotic therapy than do C. trachomatis-negative men, while others have found no difference, and the reverse was observed in one study [7, 9, 27] .
The reason for the variance in these observations is unclear [9] . It may be that in some studies men with persistent or recurrent NGU were included in the C. trachomatis-negative group and therefore biased the findings. Only one patient in our study had had NGU within the previous month, and three patients had had NGU within the prior 3 months.
We speculate that another potential source of bias is the sensitivity of the tests used to detect persistent urethritis. The persistent inflammatory response following chlamydial urethri-tis is less marked than that following nonchlamydial urethritis [25] . Thus, the use of relatively less sensitive tests for urethral inflammation at follow-up may underrepresent objective chronic NGU in patients with chlamydial urethritis.
We also found a significant association between the serological response to chlamydial hsp60 and the subsequent development of chronic urethritis. It was interesting that there was a temporal relationship between hsp60 antibody and chronic NGU. The presence of hsp60 antibody both at presentation and during follow-up to day 29 was associated with chronic NGU at 10-29 days, but the presence of hsp60 antibodies only during follow-up was associated with chronic NGU at 30-92 days. This suggests that hsp60 antibody may be causally related to the urethral inflammation.
Toye et al. [21] observed a chlamydial hsp60 serological response primarily in women with C. trachomatis antibody. Only 1 of 166 patients without antibody to C. trachomatis had chlamydial hsp60 antibody. Indeed, the association of the inflammatory sequelae of pelvic inflammatory disease with hsp60 antibodies was demonstrated by Toye et al. [21] and Wagar et al. [20] only in women who were C. trachomatis antibody-positive.
We also found an association between chlamydial hsp60 antibody and the development of chronic NGU in patients who were either C. trachomatis-positive or C. trachomatis antibody-positive. This association was not significant for patients who were positive only for C. trachomatis, but the number of such patients in our study was small, and it may be that the lack of a significant association within this group was a type II statistical error.
We found a significant association of C. trachomatis antibody and C. trachomatis detection with chlamydial hsp60 antibody. We also measured Chlamydia pneumoniae antibody in our patients, as C. trachomatis hsp60 has a high degree of homology with C. pneumoniae hsp60 [28] . Of 32 patients with hsp60 antibody during the study who were evaluable for determination of chlamydial antibody status, six (19%) had no antibodies to Chlamydia species.
This finding is consistent with our previous observation that patients who do not have antibody to either Chlamydia species can have antibodies to chlamydial hsp60 [24] . Antibodies to hsp60 are not uncommon in humans. As this protein is highly conserved, one would expect to find subjects who have never been infected with chlamydiae to have hsp60 antibodies that cross-react with chlamydia hsp60. This has been observed for mycobacterial hsp65 [29] .
Beatty et al. [11] have proposed that persistent latent chlamydial infection is the cause of chronic inflammation and disease in patients with trachoma and pelvic inflammatory disease. It has been shown in vitro that C. trachomatis can exist as aberrant reticulate bodies that have decreased levels of major outer membrane protein and lipopolysaccharide and do not produce infectious elementary bodies [30] . C. trachomatis is detected with use of antibodies to these antigens or by culture of the microorganism. Thus, in studies in which these techniques have been used, a significant proportion of patients with persistent chlamydial infection may have been missed. In contrast, the sensitivity of the PCR assay for C. trachomatis should not be affected by the formation of aberrant reticulate bodies.
Our findings are not consistent with the persistence of C. trachomatis infection after appropriate treatment. This is in agreement with the findings of other investigators who, using the PCR assay, have studied men with chlamydial genital tract infection [7, 31] . We found only two patients to be C. trachomatis-positive during follow-up. One was positive only by the PCR assay at the first follow-up visit, and subsequent tests for C. trachomatis were negative, although his urethritis persisted.
The other patient had been treated with tetracycline in the month prior to enrollment. He was C. trachomatis-negative at presentation and PCR-and DFA-negative at the first followup visit, when it was found that his urethritis had resolved. NGU subsequently recurred and PCR and DFA tests became positive, events consistent with transmission of C. trachomatis from his untreated partner. However, despite declining to have treatment until both he and his partner could be seen together, he became both PCR-and DFA-negative, although urethritis persisted. This suggests that the immune response may have resolved the chlamydial infection.
It has been suggested that hsp60 may have a role in autoimmunity because of the high degree of protein homology between hsp60 in microorganisms and human hsp60, which could lead to a breakdown in self-tolerance to human hsp60 [17, 19] . In this study we assessed the serological response only to the chlamydial hsp60. It is interesting that this was detected in C. trachomatis-negative men, suggesting that other microorganisms can lead to the development of an hsp60 serological response.
Two candidates might be M. genitalium and U. urealyticum, and the possibility of their involvement requires further investigation. Although we did not investigate the T cell response to hsp60, our findings would be consistent with the production of hsp60 by certain microorganisms during acute NGU, leading to a breakdown in self-tolerance to human hsp60. Another hypothesis would be that certain microbial hsp60s, in particular that of Chlamydia species, lead to a cross-sensitization to other, nonpathogenic microbial hsp60s.
Commensal bacteria in the male urethra would then, through the production of their own hsp60, become a focus for inflammation. Certainly the male anterior urethra has numerous commensal bacteria, as indicated by gram-stained urethral smears. This might explain why antibiotics are sometimes effective in treating chronic clinically symptomatic NGU, despite the failure to identify persistent infection.
In conclusion, although chronic NGU in men is a complex condition that is probably multifactorial in etiology, our results are consistent with the theory that the immune response to hsp60 is important in the development of this chronic disease. We detected C. trachomatis only rarely during follow-up and found no association of chronic NGU with C. trachomatis detection at presentation, which suggests that the disease is not a consequence of continued production of hsp60 by C. trachomatis. The idea that an immunologic mechanism is involved, such as the breakdown of self-tolerance to human hsp60, requires further investigation.
